Phagelux Provides Updates Including Expansion

Phagelux, Inc announced the raise of expansion capital from Fosun Industrial Co. Ltd., a subsidiary of Fosun Pharmaceutical Group (600196.SH, 02196.HK).
According to Mark Engel, CEO of Phagelux:

The addition of Fosun as a strategic partner is a milestone for our company since Fosun brings with them strong expertise in drug development, drug distribution and access to global equity markets.

Click here to view the full press release.